SEC 13F Intelligence

Propel Bio Management, LLC / FULC

Propel Bio Management, LLC’s Fulcrum Therapeutics Inc Position

Does Propel Bio Management, LLC own Fulcrum Therapeutics Inc (FULC)? Not currently — the last reported position was 750.0K shares worth $5M in Q2 2024; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$5M
Q2 2024
Shares
750.0K
% of Portfolio
+3.02%
Quarters Held
3
position exited

Position History FULC

Reported value by quarter
Q4 ’23: $5MQ4 ’23Q1 ’24: $7MQ1 ’24Q2 ’24: $5MQ2 ’24filingsflow.com
QuarterSharesValue% of Portfolio
Q2 2024750.0K$5M+3.02%
Q1 2024750.0K$7M+4.12%
Q4 2023750.0K$5M+4.20%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Propel Bio Management, LLC’s full portfolio or all institutional holders of FULC.